Percutaneous Coronary Intervention Pharmacology From a Triangle to a Square⁎⁎Editorials published in the Journal of American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. by Dauerman, Harold L.
P
I
F
H
B
I
m
t
(
m
1
w
b
3
3
c
c
E
E
a
m
(
w
O
c
s
e
E
T
o
(
c
c
d
i
m
c
c
(
b
m
M
T
u
a
a
m
i
i
C
t
h
m
w
e
m
A
t
i
b
s
a
m
I
f
l
b
s
“
h
i
a
c
t
T
a
S
t
(
b
a
p
p
i
I
p
*
o
C
D
a
Journal of the American College of Cardiology Vol. 51, No. 7, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.042EDITORIAL COMMENT
ercutaneous Coronary
ntervention Pharmacology
rom a Triangle to a Square*
arold L. Dauerman, MD, FACC
urlington, Vermont
n this issue of the Journal, Ndrepepa et al. (1) present a
eta-analysis of 4 ISAR (Intracoronary Stenting and An-
ithrombotic Regimen) percutaneous coronary intervention
PCI) trials suggesting that bleeding complications and
yocardial infarction (MI) are equivalent predictors of
-year mortality after PCI. Among 5,384 ISAR patients
ith a broad spectrum of coronary syndromes and risk,
leeding in the first 30 days after PCI conferred a nearly
-fold increased risk of dying at 1 year. The end points of
0-day bleeding, MI, and urgent revascularization had a
omparable ability to predict 1-year death. These results are
ongruent with analyses of the REPLACE-2 (Randomized
valuation in PCI Linking Angiomax to Reduced Clinical
vents) trial comparing PCI using bivalirudin versus hep-
rin and glycoprotein IIb/IIIa inhibitor (GPI); patients with
ajor bleeding had a similar relative risk of 1-year mortality
2.66, 95% confidence interval 1.44 to 4.92) as did those
ith MI (2.46, 95% confidence interval 1.44 to 4.20) (2).
See page 690
n the basis of this observation, should we change our
linical trials of PCI pharmacology to place a traditional
afety end point (bleeding) equivalently into the primary
fficacy end point (death, MI, and urgent revascularization)?
arly Bleeding, Late Death
he complication of retroperitoneal bleeding is a clinically
bvious connection between bleeding and hospital death
3). The more general association between major bleeding
omplications and early mortality among patients with acute
oronary syndromes and PCI has also been previously
escribed (4,5). But, the current meta-analysis provides 3
nsights that challenge our current trial designs and phar-
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
ollege of Cardiology.
From the University of Vermont College of Medicine, Burlington, Vermont. Dr.o
auerman is on the steering committee for the CHAMPION PCI (cangrelor) trial
nd a consultant to The Medicines Company.acology choices. First, bleeding events in the first 30 days
onfer an increased risk of death beyond 30 days; the curves
ontinue to diverge from 30 days (7% mortality) to 1 year
14% mortality), even though there might be no further
leeding events beyond 30 days. Second, the increased
ortality risk is associated with both Thrombolysis In
yocardial Infarction (TIMI) major and minor bleeding.
hird, the discriminatory potential (c statistic) of MI,
rgent revascularization, and bleeding for 1-year mortality
re identical (0.78).
Three pathophysiological mechanisms might explain the
ssociation among PCI, bleeding, and death. 1) Bleeding
ight be a marker for a systemic inflammatory process that
ncreases the risk of subsequent thrombosis. This hypothesis
s supported by a recent substudy of the ACUITY (Acute
atheterization and Urgent Intervention Triage strategY)
rial, suggesting that patients with bleeding complications
ave a heightened inflammatory state (6). 2) Early bleeding
ight lead to early cessation of dual antiplatelet therapy,
hich has been associated with increased cardiovascular
vents (7). 3) Bleeding leads to blood transfusions that
ight themselves lead to increased cardiovascular risk (8).
ll of these potential mechanisms might be supported by
he observation that patients who bleed are at higher risk for
schemic events (4,5).
But, how can we understand the ISAR finding that minor
leeding is a significant predictor of death? Not all bleeding
eems equivalent, just as not all periprocedural infarctions
re clinically similar (9). The issue is the definition of TIMI
inor and major bleeding. A TIMI minor bleed in the
SAR trials (clinically overt hemorrhage associated with a
all in hematocrit 15%) could include a patient with a
arge retroperitoneal bleed. This is not the same as a minor
leed as defined in later TIMI trials or in multiple other
chemas (10–12). Given this rather expansive definition of
minor,” the ISAR trial analysis is not telling us that a small
ematoma is equivalent to MI and urgent revascularization
n predicting 1-year death; rather, it is telling us that there
re some serious and misnomered bleeds conferring in-
reased risk both early after the bleed and then throughout
he first year.
he Quadruple End Point
nd Trials of Periprocedural MI
hould we accept the ISAR proposal and move from the
riangle (death, MI, urgent revascularization) to the square
death, MI, urgent revascularization, and bleeding) as the
asis for defining efficacy of future PCI pharmacology
gents (Fig. 1)? Some would argue that such a change would
revent approval of effective agents, owing to masking of the
rimary goal (prevention of infarction) by secondary bleed-
ng concerns (13). What would happen if we applied the
SAR findings to an important triple end point PCI
harmacology trial? The ESPRIT (Enhanced Suppression
f the Platelet IIb/IIIa Receptor with Integrilin Therapy)
t
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February 19, 2008:698–700 Editorial Commentrial compared aspirin, thienopyridine, eptifibatide, and
nfractionated heparin with aspirin, thienopyridine, and
eparin alone among patients undergoing elective stenting
14). The primary end point of this trial was death, MI, and
rgent revascularization, with very low rates of death and
-wave acute MI in both treatment groups. The benefit of
ptifibatide for the primary 30-day end point was robust
10.5% vs. 6.6%, p  0.0015) and led to wide use of
ptifibatide in cardiac catheterization laboratories.
But, what would happen if the primary end point had
een expanded to the square: the ESPRIT primary end
oint  major bleeding complications? Major bleeding
omplications were significantly increased in the eptifibatide
ersus placebo arms (1.3% vs. 0.4%, p  0.027). If one were
o crudely add the major bleeding events to the primary end
oint in each arm, the reduction in the 30-day primary end
oint is lessened (10.9% vs 7.9%) but still remains signifi-
ant (p  0.02 by chi-square). Notably, this crude addition
ight be an overestimate of the total number of quadruple
nd point events in ESPRIT: patients who bleed might also
e patients with MI after PCI and thus we might be double
ounting events with simple addition (4,5). But even in this
orst case scenario, the adoption of the ISAR suggested a
uadruple end point would not mask the anti-ischemic
otential of currently used adjunctive therapy.
he Quadruple End Point
nd Trials of Stent Thrombosis
hat would happen if we applied the quadruple end point
o a trial investigating PCI pharmacology aimed at prevent-
ng the devastating complication of stent thrombosis?
TARS (Stent Anticoagulation Restenosis Study) random-
zed patients undergoing bare-metal stenting to aspirin,
Figure 1 PCI Pharmacology Trials:
From the Triple to the Quadruple End Point
The current meta-analysis suggests that the primary end point of percutaneous
coronary intervention (PCI) pharmacology trials needs revision. Instead of a tri-
ple end point—death, asymptomatic creatine kinase-myocardial band (CK-MB)/
symptomatic myocardial infarction (MI), and target vessel revascularization
(TVR)—future trials might focus on the quadruple end point, which includes the
mortality risk of major bleeding. GPI  glycoprotein IIb/IIIa inhibitor.spirin and warfarin, or aspirin and ticlopidine (15). The framatic reduction in stent thrombosis with dual antiplate-
et therapy compared with aspirin alone (0.5% vs. 2.9%, p
.005) is the basis for the current standard of care in PCI
harmacology. In STARS, major bleeding complications
ere 3-fold higher in the dual versus single antiplatelet
herapy group (5.5% vs. 1.8%, p 0.001). If one were to use
rude addition to assemble a quadruple end point for
TARS (primary end point  bleeding), the trend would
o longer favor dual antiplatelet therapy as the standard of
are after stenting (5.4% event rate for aspirin vs. 6.0% for
ual antiplatelet therapy, p  NS).
This example lends caution to the use of the quadruple end
oint outside of the ISAR-style trial designs that have clearly
inked major bleeding to adverse outcomes. The ISAR trials
nvestigated the utility of pharmacology regimens designed to
educe primarily asymptomatic periprocedural MI. STARS
id not include asymptomatic periprocedural infarctions in the
rimary end point. Thus, STARS is a different kind of PCI
harmacology trial in which bleeding complications are not yet
emonstrated to be comparable to the type of infarction (stent
hrombosis, Q-wave, or ST-segment elevation) being primar-
ly prevented. In future PCI pharmacology trials with the
rimary goal of preventing post-PCI death, Q-wave MI, or
tent thrombosis, the quadruple end point may not necessarily
pply.
he Future of Net Clinical Benefit
his proposed change to a quadruple end point for many
CI pharmacology trials is contingent on a new consensus
erminology for bleeding (10–12). Major bleeding needs a
ingle, predictive definition across trials. Minor bleeding
hould reflect a situation that would not impact mortality.
his rationale for uniformity of bleeding definitions is
nalogous to the need for a uniform definition of ischemic
vents across PCI trials (16). At this point, the quadruple
nd point should be applied only to populations similar to
hose in the ISAR trial analysis; for example, the 1-year
mpact of major bleeding complications as opposed to
ecurrent infarction is unknown in higher-risk patient
roups (i.e., patients with cardiogenic shock) (17).
The ISAR proposal of balancing bleeding and ischemic
oncerns in a composite end point estimating the “net
linical benefit” of a drug might seem new and controversial
18). But, the concept is at least 15 years old: for example,
he landmark GUSTO-1 (Global Utilization of Streptoki-
ase and Tissue Plasminogen Activator for Occluded Cor-
nary Arteries) trial compared different fibrinolytic strate-
ies and had a primary end point of mortality (19); the
econdary end point, however, was “net benefit, defined as a
eduction in mortality and disabling stroke.” Thus, the
SAR group’s proposal of expanding the primary goal of our
CI pharmacology trials from the triangle to the square is
ot entirely revolutionary; rather, it continues our emphasis
n developing adjunctive pharmacology that derives benefit
rom being both safe and effective.
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